306 related articles for article (PubMed ID: 31841183)
1. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
2. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
3. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
4. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Li B; Yang J; Lu Z; Liu B; Liu F
J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
[TBL] [Abstract][Full Text] [Related]
5. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
6. Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.
Zhao HW; Zhou N; Jin F; Wang R; Zhao JQ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5336-5344. PubMed ID: 32495867
[TBL] [Abstract][Full Text] [Related]
7. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
9. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J; Liu S; Yang X; Cao S; Zhou Y
Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
[TBL] [Abstract][Full Text] [Related]
10. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
Wang C; Huang H
Biochem Biophys Res Commun; 2021 Nov; 579():181-187. PubMed ID: 34624736
[TBL] [Abstract][Full Text] [Related]
11. [Saikosaponin D regulates apoptosis and autophagy of pancreatic cancer Panc-1 cells via Akt/mTOR pathway].
Guan YH; Liu GM; Liu YS; Lan LB; Zheng R; Liu XB
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5278-5284. PubMed ID: 38114117
[TBL] [Abstract][Full Text] [Related]
12. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
13. [A novel chemo-resistant gene MSX2 discovered by establishment of two pancreatic cancer drug resistant cell lines JF305/CDDP and PANC-1/GEM].
Yuan W; Sui CG; Ma X; Ma J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):330-334. PubMed ID: 29860758
[No Abstract] [Full Text] [Related]
14. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K
Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865
[TBL] [Abstract][Full Text] [Related]
15. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
[TBL] [Abstract][Full Text] [Related]
16. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract][Full Text] [Related]
17. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
18. Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.
Shen Z; Xue D; Wang K; Zhang F; Shi J; Jia B; Yang D; Zhang Q; Zhang S; Jiang H; Luo D; Li X; Zhong Q; Zhang J; Peng Z; Han Y; Sima C; He X; Hao L
BMC Urol; 2022 May; 22(1):79. PubMed ID: 35610639
[TBL] [Abstract][Full Text] [Related]
19. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
20. Metformin induces apoptosis of melanoma B16 cells via PI3K/Akt/mTOR signaling pathways.
Tian Y; Zhao L
J BUON; 2020; 25(4):2066-2070. PubMed ID: 33099954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]